Side effects, or what are known as co-morbidities, often discourage men who have metastatic prostate cancer from continuing with chemotherapy (docetaxel). The question often asked is there a relationship between having side effects and the ultimate efficacy of the chemotherapy? In other words does having side effects have an effect on overall survival? To answer [...]
For cancer, January 2016 has been an unusual month. This January, cancer has managed to take the lives of three world renowned entertainers; David Bowie, Alan Rickman and Terry Wogan. Examining their deaths, we see that they all were marked with great outpourings of grief from their loved ones, colleagues and their fans. But they [...]
According to an article in the Journal of Nuclear Medicine, researchers compared a PET/CT scan using the radiotracer F-18 DCFBC to conventional imaging modalities — an expanded Tc-99m-methylene diphosphonate (MDP) bone scan and contrast-enhanced CT of the chest, abdomen and pelvis — to detect prostate-specific membrane antigen (PSMA), which is associated with prostate cancer metastases. [...]
There is a paradigm shift happening around us in the clinical care of men with metastatic hormone-sensitive prostate cancer. We now know that survival is better when docetaxel chemotherapy is added to androgen-deprivation therapy (ADT), but there have been and still remains concerns about the toxicity of the docetaxel. Recent findings from a new study, [...]
In General the use of a PSA value in excess of 4.0 µg/L is considered a clinical indicator for men at risk for prostate cancer. But, is this a good prognostic indicator in men who are HIV Positive? Researchers found that PSA was highly predictive of prostate cancer in men with HIV; however the commonly [...]